FDA upholds rejection of Echo IQ's EchoSolv HF heart-failure AI after appeal
The FDA kept its “not substantially equivalent” finding; Echo IQ shares fell 42% and the company is weighing a new 510(k), while its EchoSolv AS tool stays cleared.
The FDA kept its “not substantially equivalent” finding; Echo IQ shares fell 42% and the company is weighing a new 510(k), while its EchoSolv AS tool stays cleared.